Oncothyreon appoints new R&D vice president
This article was originally published in Scrip
Executive Summary
Biotechnology company Oncothyreon, which specialises in the development of innovative therapeutic oncology products, has appointed Dr Scott Peterson as vice-president of R&D, effective August 1st. In his new role, Dr Peterson will oversee preclinical and non-clinical R&D activities at the company. Dr Peterson previously worked at Zymogenetics, where he served as director and department head of oncology research; prior to this, he held the role of principal scientist in oncology drug discovery at ICOS Corporation.